US 2018/0000847 A1Published application

Crystallization method and bioavailability

AssigneeGrüNenthal GmbH

InventorMazen HANNA

Life of this patent

Estimating the term…

Abstract

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Claims20

Dependent claims

A method of treating psoriatic arthritis, said method comprising the step of administering to a psoriatic arthritis patient a therapeutically effective amount of a crystalline molecular complex of zoledronic acid, lysine and water.

Dependencies are inferred from the claim text.

Facts

Application: 15/609,641Filed 31 May 2017
Priority: 31 May 2016
Published: 4 Jan 2018
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 31/663
Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon: compounds having two or more phosphorus acid groups or esters…
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 31/4164
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: 1,3-Diazoles
A61K 31/662
Phosphorus compounds: phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon

Family

Application62/343,509Us provisional application · filed 31 May 2016
US 10,195,218 B2Related patent
US 2018/0000847 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results